# G9-TMB

## Supplementary Resource to:  

Karn T et al. Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.
[doi: 10.1016/j.annonc.2020.05.015](https://doi.org/10.1016/j.annonc.2020.05.015)

*Pubmed:*

[https://www.ncbi.nlm.nih.gov/pubmed/?term=32461104](https://www.ncbi.nlm.nih.gov/pubmed/?term=32461104)

************************************************************

## This resource contains the following data described in the paper:


* [< Supplementary-Methods.pdf >](https://github.com/tkarn/G9-TMB/blob/master/Supplementary-Methods.pdf)

    Supplementary Methods

    
* [< SuppTab-S1.pdf >](https://github.com/tkarn/G9-TMB/blob/master/SuppTab-S1.pdf)

    Suppl. Table S1: Clinical data of the complete study cohort vs. the WES cohort and the WES+RNA-Seq cohort.
    
    
* [< SuppTab-S2.pdf >](https://github.com/tkarn/G9-TMB/blob/master/SuppTab-S2.pdf)

    Suppl. Table S2: Logistic regression of pCR using TMB and immune GEP
    
    
* [< SuppTab-S3.pdf >](https://github.com/tkarn/G9-TMB/blob/master/SuppTab-S3.pdf)

    Suppl. Table S3: Logistic regression of pCR using TMB and TILs
    
    
* [< SuppTab-S4.pdf >](https://github.com/tkarn/G9-TMB/blob/master/SuppTab-S4.pdf)

    Suppl. Table S4: Correlation of TMB with molecular subtypes and genomic alterations
    
    
* [< SuppTab-S5.pdf >](https://github.com/tkarn/G9-TMB/blob/master/SuppTab-S5.pdf)

    Suppl. Table S5: AIMS gene pairs included in HTG EdgeSeq Oncology Biomarker Panel
    
    
* [< SuppFig-S1.pdf >](https://github.com/tkarn/G9-TMB/blob/master/SuppFig-S1.pdf)

    Supplementary Figure S1: CONSORT diagram of the flow of samples through the study
    
    
* [< SuppFig-S2.pdf >](https://github.com/tkarn/G9-TMB/blob/master/SuppFig-S2.pdf)

    Supplementary Figure S2: Association of pathological complete response and TMB in GeparNuevo

* [< SuppFig-S3.pdf >](https://github.com/tkarn/G9-TMB/blob/master/SuppFig-S3.pdf)

    Supplementary Figure S3: Joint relationship of TMB and immune gene expression profile with pCR separately within the treatment arms of GeparNuevo

* [< SuppFig-S4.pdf >](https://github.com/tkarn/G9-TMB/blob/master/SuppFig-S4.pdf)

    Supplementary Figure S4: Joint relationship of TMB and TILs with pCR in GeparNuevo

* [< SuppFig-S5.pdf >](https://github.com/tkarn/G9-TMB/blob/master/SuppFig-S5.pdf)

    Supplementary Figure S5: Relationship of TMB and immune GEP in samples with specific copy number gains in GeparNuevo patients

* [< SuppFig-S6.pdf >](https://github.com/tkarn/G9-TMB/blob/master/SuppFig-S6.pdf)

    Supplementary Figure S6: Quality control of RNA sequencing data from HTG EdgeSeq

* [< SuppFig-S7.pdf >](https://github.com/tkarn/G9-TMB/blob/master/SuppFig-S7.pdf)

    Supplementary Figure S7: Correlation of different T-cell signatures from HTG EdgeSeq data
    
* [< SuppFig-S8.pdf >](https://github.com/tkarn/G9-TMB/blob/master/SuppFig-S8.pdf)

    Supplementary Figure S8: Integrated view of parameters in GeparNuevo samples

